Core Viewpoint - Robbins LLP has announced a class action lawsuit against Vital Farms, Inc. for allegedly misleading investors regarding its business prospects during the period from May 8, 2025, to February 26, 2026 [1][2]. Allegations - The lawsuit claims that Vital Farms made false and misleading statements about the implementation of an enterprise resource planning (ERP) system, which was said to be crucial for operational improvements [2]. - Defendants allegedly did not disclose that the ERP implementation would lead to delays in shipments and production, which could negatively impact the company's business [2]. - The complaint highlights that management was aware of potential issues surrounding the ERP implementation but failed to adequately inform investors [2]. Financial Performance - On February 26, 2026, Vital Farms reported its fiscal year 2025 revenue at $759.44 million, which was below the guidance of $775 million [3]. - The company also reported earnings per share (EPS) of $0.35, missing the market consensus of $0.39 [3]. - Following the release of this information, Vital Farms' stock price fell by $2.68, or 10.8%, closing at $22.11 [3]. Class Action Participation - Shareholders who purchased Vital Farms securities during the specified period may be eligible to participate in the class action lawsuit [4]. - Interested parties can contact Robbins LLP to serve as lead plaintiff or to receive further information [4]. Company Background - Vital Farms is recognized as a leading U.S. brand of pasture-raised eggs and the second-largest U.S. egg brand by retail dollar sales [1].

Group 1 - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare industries, highlighting key trends and catalysts that influence market valuations [1] - The newsletter is led by a biotech consultant with over 5 years of experience, who has compiled detailed reports on more than 1,000 companies [1] - The investing group provides insights for both novice and experienced investors, including buy and sell ratings, product sales forecasts, and integrated financial analyses [1]

Core Viewpoint - ImmunityBio, Inc. is facing a class action lawsuit due to alleged misleading statements regarding its lead product, Anktiva, which is claimed to be a cancer treatment. The lawsuit highlights significant concerns about the company's marketing practices and the efficacy claims of its product [1][4][5]. Company Overview - ImmunityBio is a biotechnology company focused on developing next-generation immunotherapies, with Anktiva being its lead biologics product [3]. Allegations of the Lawsuit - The lawsuit alleges that ImmunityBio made false claims about Anktiva, including that it would allow all NMIBC patients to be cancer-free long-term, which has not been proven [4]. - It is claimed that the assertion that Anktiva is a cancer vaccine is false, and the Executive Chairman overstated the product's capabilities [4]. - A warning letter from the U.S. FDA indicated that promotional materials misbranded Anktiva, leading to a 21% drop in stock price following the news [5]. Legal Process - Investors who purchased ImmunityBio securities during the specified class period (January 19, 2026, to March 24, 2026) can seek to be appointed as lead plaintiff in the class action lawsuit [1][6]. - The lead plaintiff will represent the interests of all class members and can choose a law firm to litigate the case [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud litigation, having recovered over $916 million for investors in 2025 alone, and $8.4 billion over the past five years [7].

Core Insights - The Growth Stock Forum focuses on identifying attractive growth stocks, particularly in the biotech sector, emphasizing risk/reward situations [1] - The biotech Top Picks of the forum achieved a remarkable increase of 137.6% last year, with a compound annual growth rate (CAGR) of 35.3% since 2017 [1] - The core portfolio, LTGP, has also demonstrated strong performance with a CAGR of 23.2% as of March 20, 2026 [1]

Core Viewpoint - A class action lawsuit has been filed against ImmunityBio, Inc. for allegedly misleading investors about its lead product, Anktiva, during the specified class period from January 19, 2026, to March 25, 2026 [1][2]. Allegations - The complaint claims that Soon-Shiong, a defendant in the case, materially overstated the capabilities of Anktiva, which is intended for treating a specific type of bladder cancer [2]. - A warning letter from the U.S. Food and Drug Administration (FDA) was publicized on March 24, 2026, indicating that promotional communications created a misleading impression that Anktiva could cure and prevent all cancers [3]. Market Impact - Following the release of the FDA warning letter, ImmunityBio's stock price fell by $1.98 per share, representing a 21% decline, closing at $7.42 per share on March 24, 2026 [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit their papers to the court by May 26, 2026. Participation in the case is not required to be eligible for recovery [4]. Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses for representation [5].

Core Viewpoint - United Therapeutics is demonstrating resilience in the biotech sector, maintaining its position in a buy zone despite a broader market decline, making it a stock to watch this week [1]. Group 1: Stock Performance - After a period of consolidation, United Therapeutics' stock broke out from a flat base on February 25, surpassing a buy point of 519.99 following strong earnings that increased the stock by over 13% [2]. - The stock's relative strength line has shown a significant upward trend, with a Relative Strength Rating of 92, indicating it has outperformed 92% of companies in the database over the past year [3]. - The stock holds a Composite Rating of 97 and an Accumulation/Distribution Rating of A-, reflecting robust institutional support [3]. Group 2: Financial Performance - United Therapeutics reported earnings of $7.70 per share in the fourth quarter, marking a 24% increase, with sales reaching $790.2 million, a 7% growth [5]. - Revenue from the drug Tyvaso grew by 12% to $464.3 million in the fourth quarter of 2025, compared to $415.9 million in the same quarter of 2024 [6]. Group 3: Future Growth Potential - The CEO of United Therapeutics, Martine Rothblatt, highlighted promising results from clinical programs that could lead to significant growth, with upcoming data from the Advance Outcomes and Teton-1 programs expected to unlock new treatment options [7].

Market Overview - The U.S. stock market experienced significant selling pressure, with all three major benchmarks trading in the red, indicating a "risk-off" sentiment among investors [1] - The Dow Jones Industrial Average fell by 703.99 points (1.53%) to 45,256.12, the S&P 500 decreased by 95.26 points (1.47%) to 6,381.90, and the NASDAQ Composite dropped by 429.35 points (2.01%) to 20,978.73 [2] Volatility and Investor Sentiment - The CBOE Volatility Index surged by 10.61% to 30.35, indicating heightened investor anxiety, with a level above 30 suggesting potential turbulent price action [3] - Small-cap stocks also faced declines, with the Russell 2000 falling by 1.58% to 2,453.94 [3] Sector Performance - The commodities sector showed resilience, with energy and metals leading gains; the United States Oil Fund rose by 4.79%, supported by a 4.36% increase in Crude Oil Futures, now at $98.60 per barrel [4] - Precious metals acted as a hedge against market declines, with Gold Futures increasing by 2.47% to $4,517.70, positively impacting the VanEck Gold Miners ETF and Junior Gold Miners ETF [5] High-Growth and Speculative Sectors - High-growth sectors were hit hard, with the ARK Genomics Revolution ETF declining by 5.66%, and the cryptocurrency market also facing losses; the iShares Bitcoin Trust fell by 4.33% and the iShares Ethereum Trust by 3.55% [6] - The Consumer Discretionary Select Sector SPDR Fund decreased by 2.70%, reflecting concerns about inflation's impact on consumer spending [6] Corporate Earnings and News - Carnival Corporation reported Q1 2026 earnings with an estimated EPS of $0.18, but the stock was affected by the broader market downturn [7] - In the biotech sector, Artelo Biosciences Inc. saw a significant price surge of 149.8% due to positive clinical developments, while Onconetix Inc. and VisionSys AI Inc. also experienced notable gains [8] Large-Cap Tech Performance - Large-cap tech stocks contributed to the NASDAQ's decline, with Nvidia, Apple, and Microsoft facing downward pressure amid a general rotation out of high-valuation tech stocks [9] - The 30-year Treasury Yield increased to 4.957%, making future earnings for growth stocks less attractive [9] Upcoming Earnings Reports - Investors are preparing for a busy week ahead, with Progress Software Corporation scheduled to report earnings on March 30, followed by several other companies including McCormick & Company and TD SYNNEX Corporation on March 31 [10] - The most anticipated report will be from Nike Inc. on March 31, providing insights into global consumer health [11]

Core Viewpoint - Evercore ISI downgraded Upstream Bio from Outperform to In Line and reduced its price target from $40 to $15, resulting in a more than 6% decline in shares during pre-market trading [1] Group 1: Company Analysis - The firm remains optimistic about the long-term potential of verekitug but is concerned about the lack of meaningful catalysts in the next 12 months [1] - There is an ongoing financing overhang and uncertainty regarding the competitiveness of the company's COPD trial, with potential dosing challenges persisting until a new dose arm is introduced [2] Group 2: Investment Outlook - Given the current factors, the firm is stepping to the sidelines in the near term, expecting shares to trade in line with the broader biotechnology sector [2] - Analysts suggest that investors with a longer-term perspective may find the current valuation an attractive entry point [2]

Core Insights - ClearBridge Small Cap Growth Strategy underperformed the Russell 2000 Growth Index in Q4 2025, following strong performance in the first three quarters of the year due to market overreactions to earnings disappointments in the technology sector and a biotech rally [1] - The small-cap sector has struggled to outperform large caps, reflecting trends from the past two years, although signs of broadening market leadership are emerging as the Strategy looks forward to 2026 [1] Company Highlights - Dyne Therapeutics, Inc. (NASDAQ:DYN) is a clinical-stage company focused on developing therapeutics for neuromuscular diseases, with a market capitalization of $2.98 billion [2] - Dyne Therapeutics closed at $18.55 per share on March 26, 2026, with a one-month return of 15.69% and a 52-week gain of 57.82% [2] - The Strategy initiated an investment in Dyne Therapeutics during Q4 2025, recognizing its potential due to limited existing treatment options and encouraging early clinical data [4] Investment Strategy - The Strategy emphasized the importance of maintaining sell discipline in businesses where fundamentals have changed, while also identifying high-quality investments across various growth categories [3] - The gradual reopening of capital markets and dynamic trends across end markets are seen as opportunities for identifying new investment ideas [3]

Core Insights - Hofseth BioCare ASA ("HBC") has approved its financial statements for 2025 and published its Annual Report and Sustainability Report for the same year [1] - The company successfully placed new ordinary shares with gross proceeds of NOK 158 million in October 2025, although the transaction is not yet completed due to technical and legal delays [1] - The completion of the share transaction is expected in Q2 2026, which will strengthen the company's balance sheet and support growth [1] Company Overview - HBC is a Norwegian consumer and pet health company focused on sustainability and optimal utilization of natural resources [2] - The company upcycles side streams from the salmon industry into health-improving ingredients such as ProGo®, OmeGo®, and CalGo® / NT-II® [2] Scientific and Health Benefits - HBC emphasizes scientific evidence, leading to academic partnerships and the identification of unique health benefits [3] - ProGo® enhances iron metabolism, OmeGo® supports immune health, and CalGo® promotes bone and joint health [3] Patents and Biotech Ventures - HBC has secured multiple patents for its discoveries and has established a biotech-focused subsidiary, HBC Immunology (HBCI), which is developing therapeutics for prostate and ovarian cancer, as well as an oral therapy for asthma [4] Company Listings - HBC is listed on Oslo Børs under the ticker "HBC" [5]